Actinogen Medical Ltd
Actinogen Medical Ltd is a biotechnology company focused on the development of novel antibiotics and antimicrobial therapies to address drug-resistant infections.
Business. Actinogen Medical Ltd (ACW.AX) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and headquarters location are not provided in the available data.
Analyst recommendations
1 analysts · consensus BuyAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Actinogen Medical Ltd (ACW.AX) is a biotechnology and medical research company operating within the healthcare sector. The firm is primarily listed on the Australian Securities Exchange. Specific details regarding its operating segments and headquarters location are not provided in the available data.
Actinogen Medical Ltd operates with a fully diluted share count of 3,588,706,510 shares, with no difference between basic and diluted shares outstanding, indicating no dilution from stock options or convertible instruments. The company's liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents.
The company's profitability and returns are not currently available for comparison to industry benchmarks, as no revenue, EBITDA, or ROIC data is present in the valuation snapshot. This lack of financial data limits the ability to assess performance relative to the Biotechnology & Medical Research industry.
Actinogen's revenue concentration and geographic exposure are not disclosed in the available data, making it difficult to evaluate the company's risk from regional market dependencies or segment-specific performance.
The company's growth trajectory is not quantifiable at this time, as no revenue history or outlook data is available. Analysts have assigned a mean price target of 0.08 AUD, with a median and high target also at 0.08 AUD, and a mean recommendation of 2.00 (indicating a "Buy" rating).
The company's risk profile is marked by low dilution potential and an inability to assess liquidity risk. No dilution sources are identified in the risk assessment, and no adjustments are applied in the custom valuations.
No recent events, such as filings or transcripts, are available in the source documents to inform the company's current strategic or operational direction.
- Actinogen Medical Ltd has no difference between basic and diluted shares outstanding, indicating no dilution from options or convertibles.
- Analysts have assigned a "Buy" rating with a mean price target of 0.08 AUD.
- The company's financial performance and growth trajectory cannot be assessed due to the absence of revenue and profitability data.
- Liquidity risk could not be evaluated due to missing balance-sheet inputs.
- No recent events or disclosures are available to inform the company's strategic direction.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Revenue A$685.2k, +135,5% YoY; Operating income −13,1% YoY.
- ▍Revenue A$685.2k, +135,5% YoY
- ▍Operating income −13,1% YoY
- ▍Net income −12,9% YoY
- ▍Free cash flow −13,6% YoY
- ▍Net margin -2149.9%
Revenue A$291.0k, −20,6% YoY; Operating income −22,1% YoY.
- ▍Revenue A$291.0k, −20,6% YoY
- ▍Operating income −22,1% YoY
- ▍Net income −21,3% YoY
- ▍Free cash flow −21,7% YoY
- ▍Net margin -4482.3%
Revenue A$366.6k, +792,7% YoY; Operating income −11,9% YoY.
- ▍Revenue A$366.6k, +792,7% YoY
- ▍Operating income −11,9% YoY
- ▍Net income −13,2% YoY
- ▍Free cash flow −14,1% YoY
- ▍Net margin -2932.6%
Revenue A$41.1k, +51,6% YoY; Operating income −143,8% YoY.
- ▍Revenue A$41.1k, +51,6% YoY
- ▍Operating income −143,8% YoY
- ▍Net income −142,6% YoY
- ▍Free cash flow −157,4% YoY
- ▍Net margin -23124.8%
Revenue A$27.1k; Operating income -A$3.9M.
- ▍Revenue A$27.1k
- ▍Operating income -A$3.9M
- ▍Net margin -14452.1%
Valuation FY
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | -0,01 |
| Revenue | —no estimate | —no estimate | 5,5M AUD |
| Operating income | —no estimate | —no estimate | -19,2M AUD |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Actinogen Medical Ltd Market data — financials · 2026-05-27
- Actinogen Medical Ltd Market data — analyst estimates · 2026-05-27